Want to see FR:NANO full AI Analyst Report?
NANO Stock Chart & Stats
€35.74
-€0.84(-2.38%)
At close: 4:00 PM EDT
€35.74
-€0.84(-2.38%)
Day’s Range― - ―
52-Week Range€11.80 - €47.66
Previous CloseN/A
Volume28.17K
Average Volume (3M)157.52K
Market Cap
€1.48B
Enterprise Value€1.56K
Total Cash (Recent Filing)€110.89M
Total Debt (Recent Filing)€106.61M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Apr 27, 2027EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding50,619,583
10 Day Avg. Volume136,890
30 Day Avg. Volume157,517
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€60.00Price Target Upside67.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€21.56M
Bulls Say, Bears Say
Bulls Say
2025 Revenue GrowthThe sharp 2025 revenue increase indicates that Nanobiotix can generate stronger top-line activity as its clinical programs and collaborations advance. If sustained, expanding revenue could improve funding capacity and provide a broader base for future commercialization economics.
Proprietary Oncology PlatformNanobiotix's proprietary nanoparticle platform addresses a defined oncology need by potentially increasing the impact of radiotherapy while supporting immune responses. This differentiated mechanism may create strategic value across multiple cancer-treatment combinations if clinical development succeeds.
Janssen PartnershipThe Janssen collaboration gives Nanobiotix access to a larger biopharmaceutical partner for development and potential commercialization of NBTXR3. Such a relationship can support program execution, validate strategic relevance, and provide milestone or royalty opportunities if progress continues.
Bears Say
Persistent UnprofitabilityContinued operating and net losses show that Nanobiotix has not yet established repeatable earnings power. Until clinical programs produce sustainable commercial or collaboration income, ongoing losses can constrain investment flexibility and keep the company dependent on additional financing.
Recurring Cash BurnPersistent operating and free-cash-flow deficits indicate that reported losses are translating into real cash outflows rather than being primarily non-cash. Limited internal funding capacity raises the importance of partnerships or capital raises to sustain clinical development.
Negative Equity And Rising DebtNegative shareholders' equity weakens the balance sheet and reduces financial flexibility, while rising debt increases pressure on future funding and repayment capacity. This capital structure makes it harder to absorb setbacks or finance development without external support.
NANO FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €11.80 and its highest was €47.66 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.48B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Apr 27, 2027 which is in 211 days.
How were Nanobiotix SA’s earnings last quarter?
Nanobiotix SA released its earnings results on Sep 24, 2026. The company reported -€0.7 earnings per share for the quarter, missing the consensus estimate of -€0.25 by -€0.45.
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is 0.05.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Nanobiotix SA reported an EPS of -€0.7 in its last earnings report, missing expectations of -€0.25. Following the earnings report the stock price went up 4.366%.
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in FR:NANO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
NANO Stock 12 Month Forecast
Average Price Target
€60.00
▲(67.88% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―